1. Home
  2. ENTA vs MSD Comparison

ENTA vs MSD Comparison

Compare ENTA & MSD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENTA
  • MSD
  • Stock Information
  • Founded
  • ENTA 1995
  • MSD 1993
  • Country
  • ENTA United States
  • MSD United States
  • Employees
  • ENTA N/A
  • MSD N/A
  • Industry
  • ENTA Biotechnology: Pharmaceutical Preparations
  • MSD Trusts Except Educational Religious and Charitable
  • Sector
  • ENTA Health Care
  • MSD Finance
  • Exchange
  • ENTA Nasdaq
  • MSD Nasdaq
  • Market Cap
  • ENTA 164.6M
  • MSD 152.3M
  • IPO Year
  • ENTA 2013
  • MSD N/A
  • Fundamental
  • Price
  • ENTA $8.83
  • MSD $7.46
  • Analyst Decision
  • ENTA Strong Buy
  • MSD
  • Analyst Count
  • ENTA 4
  • MSD 0
  • Target Price
  • ENTA $20.75
  • MSD N/A
  • AVG Volume (30 Days)
  • ENTA 173.1K
  • MSD 70.2K
  • Earning Date
  • ENTA 08-11-2025
  • MSD 01-01-0001
  • Dividend Yield
  • ENTA N/A
  • MSD 11.26%
  • EPS Growth
  • ENTA N/A
  • MSD N/A
  • EPS
  • ENTA N/A
  • MSD N/A
  • Revenue
  • ENTA $64,806,000.00
  • MSD N/A
  • Revenue This Year
  • ENTA N/A
  • MSD N/A
  • Revenue Next Year
  • ENTA $4.05
  • MSD N/A
  • P/E Ratio
  • ENTA N/A
  • MSD N/A
  • Revenue Growth
  • ENTA N/A
  • MSD N/A
  • 52 Week Low
  • ENTA $4.09
  • MSD $6.11
  • 52 Week High
  • ENTA $13.43
  • MSD $7.46
  • Technical
  • Relative Strength Index (RSI)
  • ENTA 65.93
  • MSD 47.05
  • Support Level
  • ENTA $6.45
  • MSD $7.40
  • Resistance Level
  • ENTA $7.73
  • MSD $7.48
  • Average True Range (ATR)
  • ENTA 0.55
  • MSD 0.05
  • MACD
  • ENTA 0.17
  • MSD 0.01
  • Stochastic Oscillator
  • ENTA 90.15
  • MSD 70.00

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

About MSD Morgan Stanley Emerging Markets Debt Fund Inc.

Morgan Stanley Emerg Mkts Debt Fd Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is to produce high current income and as a secondary objective to seek capital appreciation, through investments mainly in debt securities of government and government-related issuers located in emerging countries, of entities organized to restructure the outstanding debt of such issuers and debt securities of corporate issuers in or organized under the laws of emerging countries.

Share on Social Networks: